1. Home
  2. TNXP vs ALT Comparison

TNXP vs ALT Comparison

Compare TNXP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • ALT
  • Stock Information
  • Founded
  • TNXP 2007
  • ALT 1997
  • Country
  • TNXP United States
  • ALT United States
  • Employees
  • TNXP N/A
  • ALT N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TNXP Health Care
  • ALT Health Care
  • Exchange
  • TNXP Nasdaq
  • ALT Nasdaq
  • Market Cap
  • TNXP 335.6M
  • ALT 333.6M
  • IPO Year
  • TNXP N/A
  • ALT N/A
  • Fundamental
  • Price
  • TNXP $22.41
  • ALT $3.93
  • Analyst Decision
  • TNXP Buy
  • ALT Strong Buy
  • Analyst Count
  • TNXP 1
  • ALT 6
  • Target Price
  • TNXP $70.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • TNXP 1.1M
  • ALT 3.0M
  • Earning Date
  • TNXP 11-11-2025
  • ALT 11-11-2025
  • Dividend Yield
  • TNXP N/A
  • ALT N/A
  • EPS Growth
  • TNXP N/A
  • ALT N/A
  • EPS
  • TNXP N/A
  • ALT N/A
  • Revenue
  • TNXP $9,831,000.00
  • ALT $20,000.00
  • Revenue This Year
  • TNXP $14.79
  • ALT N/A
  • Revenue Next Year
  • TNXP $933.49
  • ALT N/A
  • P/E Ratio
  • TNXP N/A
  • ALT N/A
  • Revenue Growth
  • TNXP N/A
  • ALT N/A
  • 52 Week Low
  • TNXP $6.76
  • ALT $2.90
  • 52 Week High
  • TNXP $130.00
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 30.44
  • ALT 52.80
  • Support Level
  • TNXP $23.60
  • ALT $3.85
  • Resistance Level
  • TNXP $29.19
  • ALT $4.06
  • Average True Range (ATR)
  • TNXP 1.63
  • ALT 0.20
  • MACD
  • TNXP 0.12
  • ALT 0.02
  • Stochastic Oscillator
  • TNXP 5.31
  • ALT 57.35

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: